Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia

Genomics

Volumn 102, Issue 4, 2013, Pages 243-249

  Kryukov, Fedor ^a   Dementyeva, Elena ^a   Kubiczkova, Lenka ^a   Jarkovsky, Jiri ^a   Brozova, Lucie ^a   Petrik, Jakub ^a   Nemec, Pavel ^a   Sevcikova, Sabina ^a   Minarik, Jiri ^b   Stefanikova, Zdena ^c   Kuglik, Petr ^a   Hajek, Roman ^a,d,e  

^a MASARYK UNIVERSITY   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^e UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

Author keywords

Cell cycle genes; Multiple myeloma; Overall survival; Plasma cell leukemia; Time to progression

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; ATM GENE; ATR GENE; CANCER REGRESSION; CCNA1 GENE; CCND1 GENE; CCND2 GENE; CCND3 GENE; CCNE1 GENE; CDK2 GENE; CDK4 GENE; CDK6 GENE; CDKN1A GENE; CDKN1B GENE; CDKN2A GENE; CELL CYCLE REGULATION; CHEK2 GENE; CONTROLLED STUDY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MDM2 GENE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; RB1 GENE; REGULATOR GENE; SENSITIVITY ANALYSIS; SHORT TERM SURVIVAL; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; UPREGULATION;

CELL CYCLE GENES; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; TIME-TO-PROGRESSION;

AGED; AGED, 80 AND OVER; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, CDC; HELA CELLS; HUMANS; LEUKEMIA, PLASMA CELL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 84886261766     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2013.06.007     Document Type: Article

References (27)

1. Chen-Kiang S. Biology of plasma cells. Best Pract. Res. Clin. Haematol. 2005, 18(4):493-507.
2. Yu T., Bai Y. Capturing changes in gene expression dynamics by gene set differential coordination analysis. Genomics 2011, 98(6):469-477.
3. Tourigny M.R., Ursini-Siegel J., Lee H., Toellner K.M., Cunningham A.F., Franklin D.S., Ely S., Chen M., Qin X.F., Xiong Y., et al. CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. Immunity 2002, 17(2):179-189.
4. Bergsagel P.L., Kuehl W.M., Zhan F.H., Sawyer J., Barlogie B., Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005, 106(1):296-303.
5. Bergsagel P.L., Kuehl W.M. Molecular pathogenesis and a consequent classification of multiple myeloma. J. Clin. Oncol. 2005, 23(26):6333-6338.
6. Morgan G.J., Walker B.A., Davies F.E. The genetic architecture of multiple myeloma. Nat. Rev. Cancer 2012, 12(5):335-348.
7. Albarracin F., Fonseca R. Plasma cell leukemia. Blood Rev. 2011, 25(3):107-112.
8. Nemec P., Zemanova Z., Kuglik P., Michalova K., Tajtlova J., Kaisarova P., Oltova A., Filkova H., Holzerova M., Balcarkova J., et al. Complex karyotype and translocation t (4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk. Lymphoma 2012, 53(5):920-927.
9. Sevcikova S., Nemec P., Pour L., Hajek R. Genomics in multiple myeloma research. Klin. Onkol. 2011, 24:S34-S38. (Suppl.).
10. Durie B.G., Harousseau J.L., Miguel J.S., Blade J., Barlogie B., Anderson K., Gertz M., Dimopoulos M., Westin J., Sonneveld P., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20(9):1467-1473.
11. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., Eppig J.T., et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000, 25(1):25-29.
12. Haber D.A. Splicing into senescence: the curious case of p16 and p19ARF. Cell 1997, 91(5):555-558.
13. Shaughnessy J., Gabrea A., Qi Y., Brents L., Zhan F., Tian E., Sawyer J., Barlogie B., Bergsagel P.L., Kuehl M. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 2001, 98(1):217-223.
14. Zhan F., Hardin J., Kordsmeier B., Bumm K., Zheng M., Tian E., Sanderson R., Yang Y., Wilson C., Zangari M., et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002, 99(5):1745-1757.
15. Fonseca R., Blood E.A., Oken M.M., Kyle R.A., Dewald G.W., Bailey R.J., Van Wier S.A., Henderson K.J., Hoyer J.D., Harrington D., et al. Myeloma and the t (11;14) (q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002, 99(10):3735-3741.
16. Moreau P., Facon T., Leleu X., Morineau N., Huyghe P., Harousseau J.L., Bataille R., Avet-Loiseau H., Myelome I.F. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002, 100(5):1579-1583.
17. Soverini S., Martinelli G., Cavo M. Cyclin D1 expression in multiple myeloma: a pathogenetic role besides the prognostic relevance?. Blood 2003, 102(12):4246-4246.
18. Tasidou A., Roussou M., Terpos E., Kastritis E., Gkotzamanidou M., Gavriatopoulou M., Migkou M., Eleutherakis-Papaiakovou E., Nikitas N., Anagnostou D., et al. Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents. Am. J. Hematol. 2012, 87(7):734-736.
19. Durie B.G., Salmon S.E., Moon T.E. Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 1980, 55(3):364-372.
20. Caffo O., Doglioni C., Veronese S., Bonzanini M., Marchetti A., Buttitta F., Fina P., Leek R., Morelli L., Palma P.D., et al. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin. Cancer Res. 1996, 2(9):1591-1599.
21. Timmerbeul I., Garrett-Engele C.M., Kossatz U., Chen X., Firpo E., Grunwald V., Kamino K., Wilkens L., Lehmann U., Buer J., et al. Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(38):14009-14014.
22. Porter P.L., Malone K.E., Heagerty P.J., Alexander G.M., Gatti L.A., Firpo E.J., Daling J.R., Roberts J.M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 1997, 3(2):222-225.
23. Xia W., Chen J.S., Zhou X., Sun P.R., Lee D.F., Liao Y., Zhou B.P., Hung M.C. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin. Cancer Res. 2004, 10(11):3815-3824.
24. Lowe S.W., Sherr C.J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 2003, 13(1):77-83.
25. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2001, 2(10):731-737.
26. Quelle D.E., Ashmun R.A., Hannon G.J., Rehberger P.A., Trono D., Richter K.H., Walker C., Beach D., Sherr C.J., Serrano M. Cloning and characterization of murine P16(Ink4a) and P15(Ink4b) genes. Oncogene 1995, 11(4):635-645.
27. Sherr C.J. Ink4-Arf locus in cancer and aging. Wiley Interdiscip. Rev. Dev. Biol. 2012, 1(5):731-741.